Targeted dendrimer-drug conjugates

US9345781B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9345781-B2
Application numberUS-201213493691-A
CountryUS
Kind codeB2
Filing dateJun 11, 2012
Priority dateDec 11, 2009
Publication dateMay 24, 2016
Grant dateMay 24, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention provides for dendrimer conjugates useful for liver-specific delivery of therapeutic agents. The therapeutic agent is associated to the dendrimer through a enzyme-cleavable covalent linkage.

First claim

Opening claim text (preview).

What is claimed is: 1. A dendrimer conjugate comprising a structure of wherein X is NCH 3 and Y is H or OCH 3 , or a structure of wherein X is O and Y is OCH 3 wherein the agent is a therapeutic agent or an imaging agent. 2. A pharmaceutical composition comprising a dendrimer conjugate of claim 1 and a pharmaceutically acceptable carrier. 3. A method of delivering a therapeutic agent to liver cells of a subject comprising contacting liver cells with a dendrimer conjugate of claim 1 , or a composition or pharmaceutical composition comprising the same under conditions sufficient to deliver the therapeutic agent to the liver cells wherein the dendrimer conjugate comprises a therapeutic agent. 4. A method of imaging a liver cell of a liver tissue, comprising administering to the subject a dendrimer conjugate of claim 1 , or a composition or pharmaceutical composition comprising the same, in an amount effective to image the liver cell, wherein the dendrimer conjugate comprises an imaging agent. 5. The dendrimer conjugate of claim 1 , further comprising a hepatocyte-specific targeting molecule, a PEG chain, or a combination thereof. 6. The dendrimer conjugate of claim 5 , wherein the hepatocyte-specific targeting molecule is a ligand of the asialoglycoprotein receptor (ASGPR). 7. The dendrimer conjugate of claim 6 , wherein the ligand of the ASGPR is N-acetyl-galactosamine. 8. The dendrimer conjugate of claim 5 , wherein the hepatocyte-specific targeting molecule is attached to the dendrimer through a thiourea moiety, a urea moiety, a carbamate moiety, a linkage from terminal epoxide opening, an amide linkage through peptide coupling, a linkage by formation of the Shiff base, a linkage formed by reduction of Shiff base, a linkage generated by “click” chemistry, or is attached to the dendrimer through linkage to a PEG chain which is linked to the dendrimer. 9. The dendrimer conjugate of claim 5 , wherein the PEG chain is attached to the dendrimer through an acid hydrolysable linkage. 10. The dendrimer of claim 5 , wherein a first end of the PEG chain is attached the dendrimer and a second end of the PEG chain is attached to one or more hepatocyte-specific targeting molecules. 11. The dendrimer conjugate of claim 1 , wherein the dendrimer is a poly(amidoamine) (PAMAM) polymer. 12. The dendrimer conjugate of claim 11 , wherein the dendrimer is acetylated, labeled, or both acetylated and labeled. 13. The dendrimer conjugate of claim 1 , wherein the therapeutic agent is an anti-cancer therapeutic agent. 14. The dendrimer conjugate of claim 13 , wherein the anti-cancer therapeutic agent is doxirubicin. 15. The dendrimer conjugate of claim 1 , wherein the dendrimer is a G5 dendrimer.

Assignees

Inventors

Classifications

  • Polyamides, e.g. nylon (polyamino acids A61K47/62) · CPC title

  • Macromolecular compounds {, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules (peptides, proteins, polyamino acids A61K51/08; antibodies A61K51/10)} · CPC title

  • Macromolecular compounds, i.e. oligomers, polymers, dendrimers · CPC title

  • the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title

  • obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9345781B2 cover?
The invention provides for dendrimer conjugates useful for liver-specific delivery of therapeutic agents. The therapeutic agent is associated to the dendrimer through a enzyme-cleavable covalent linkage.
Who is the assignee on this patent?
El-Sayed Mohamed E H, Ensminger William, Shewach Donna, and 1 more
What technology area does this patent fall under?
Primary CPC classification A61K49/0043. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).